Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator
Albrecht Stenzinger, Brian J. Cuffel, Noman Paracha, et al.
The Oncologist (2023) Vol. 28, Iss. 5, pp. e242-e253
Open Access | Times Cited: 10

Showing 10 citing articles:

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
Vincent D. de Jager, Wim Timens, Arnaud Bayle, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100839-100839
Open Access | Times Cited: 26
Costs of biomarker testing in advanced non‐small cell lung cancer: a global study comparing next‐generation sequencing and single‐gene testing
Umberto Malapelle, Chien‐Chin Chen, Enrique de Álava, et al.
The Journal of Pathology Clinical Research (2025) Vol. 11, Iss. 2
Open Access | Times Cited: 1
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
Mary Nesline, Vivek Subbiah, Rebecca A. Previs, et al.
Oncology and Therapy (2024) Vol. 12, Iss. 2, pp. 329-343
Open Access | Times Cited: 5
Cost-effectiveness of companion BRCA testing and adjuvant olaparib treatment in patients with BRCA-mutated high-risk HER2-negative early breast cancer
Silviya Nikolova, Wenkang Ma, Gurdeep S. Sagoo, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Actionable mutational profiling in solid tumors using hybrid‐capture‐based next‐generation sequencing in a real‐world setting in Spain
Sandra Zazo, Sandra Pérez‐Buira, Nerea Carvajal, et al.
Cancer Medicine (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 2
Next-Generation Sequencing Trends among Adult Patients with Select Advanced Tumor Types
Andrea Ferreira‐Gonzalez, Brian Hocum, Gilbert Ko, et al.
Journal of Molecular Diagnostics (2024) Vol. 26, Iss. 4, pp. 292-303
Open Access | Times Cited: 2
Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression
Eva Valentina Klocker, Samantha O. Hasenleithner, Rupert Bartsch, et al.
Molecular Oncology (2024)
Open Access | Times Cited: 2
Economic assessment of NGS testing workflow for NSCLC in a healthcare setting
Davide Seminati, Vincenzo L’Imperio, Gabriele Casati, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e29272-e29272
Open Access | Times Cited: 1
The Most Disruptive Near-Term Use of AI in Cancer Care: Patient Empowerment Through Software Agents
Frank Austin Nothaft, Brad Power
AI in Precision Oncology (2024)
Closed Access
Next step of molecular pathology: next-generation sequencing in cytology
Ricella Souza da Silva, Fernando Schmitt
Journal of Pathology and Translational Medicine (2024) Vol. 58, Iss. 6, pp. 291-298
Open Access
Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer
Michael Gnant, Marija Balić, Christian F. Singer, et al.
memo - Magazine of European Medical Oncology (2024) Vol. 18, Iss. 1, pp. 4-18
Open Access
Page 1

Scroll to top